Enovis (ENOV) Gains from Investment Securities (2024 - 2025)

Enovis' (ENOV) quarterly Gains from Investment Securities came in at $1.8 million in Q4 2025, up 1900.0% year-on-year from $90000.0 in Q4 2024, and little changed on a QoQ basis from $1.8 million in Q3 2025.

Enovis (ENOV) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Enovis (ENOV) has 2 years of Gains from Investment Securities data on file, last reported at $1.8 million in Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 1900.0% year-over-year to $1.8 million in Q4 2025; TTM through Apr 2026 was $3.6 million, a 111.25% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, up 108.89% from the prior year.
  • Gains from Investment Securities for Q4 2025 stood at $1.8 million, roughly flat from $1.8 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for ENOV reached as high as $13.4 million in Q1 2024 and fell as low as -$33.5 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn
8 Smith & Nephew 26.99 Bn 26.41 Bn -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn
10 Enovis 1.61 Bn 1.58 Bn 365.49 Mn

Historic Data

Download Data
DateValue
Oct 3, 2025 1.80 Mn
Oct 3, 2025 1.80 Mn
Jul 4, 2025 1.80 Mn
Jul 4, 2025 1.80 Mn
Apr 4, 2025 1.79 Mn
Apr 4, 2025 1.79 Mn
Dec 31, 2024 -178,000.00
Dec 31, 2024 -178,000.00
Sep 27, 2024 -100,000.00
Sep 27, 2024 -100,000.00
Jun 28, 2024 -33.50 Mn
Jun 28, 2024 -33.50 Mn
Mar 29, 2024 13.40 Mn
Mar 29, 2024 13.40 Mn